EUROFINS SCIENTIFIC

Eurofins Scientific’s recent share‑option exercise and affiliated purchases were fully EMAR‑compliant, reflecting routine management activity and a modest market‑aligned price lift.

Eurofins Scientific shares rise modestly in a weak French market, showing resilience as it boosts R&D and AI‑powered bio‑analysis services for value‑based contracts and patient‑access growth.

Eurofins Scientific’s €70‑per‑share buyback boosts EPS and ROE modestly while keeping R&D capital intact—an insightful look at balanced biotech capital strategy.

Learn how pharma and biotech firms can thrive amid volatile European markets, patent cliffs, and rising M&A activity through data‑driven, value‑centric strategies.

Eurofins Scientific’s August 2026 share‑repurchase: 90k+ shares bought at upper seventies, boosting EPS and transparency under EU MAR.

Eurofins Scientific holds steady amid market swings, driven by diversified testing, regulatory gains and AI‑powered growth – a resilient model worth watching.

Alivus Life Sciences’ FY 2025‑26 report shows 16.7% revenue growth, 25% EBITDA lift, and a new 5‑year biosimilar strategy targeting ₹2.5 bn NPV.

Vimta Labs Q1 FY 2026‑27 shows resilient growth across pharma, clinical, and testing services, with a new biologics facility securing its first order.

Eurofins Scientific beats Q1 earnings expectations, drives €3.12 bn revenue growth with strategic acquisitions and a focus on biopharma testing.

Eurofins Scientific SE balances growth and value: shares rise, a €6.9 M buyback boosts EPS, and a $400 M acquisition of EMT expands its North American life‑sciences testing reach.